EL7.AI
StocksMediumUpdated•Originally published 23 July 2026•Updated 24 July 2026•
2 min read

Thermo Fisher Stock Rises as Company Raises Full-Year Guidance and Analysts Lift Targets

Key Facts

1Jefferies analyst raised Thermo Fisher Scientific price target to $630.00, suggesting a 10.02% upside.
2The company reported Q2 adjusted EPS of $6.03, surpassing the street expectation of $5.71.
3Q2 sales climbed 10% year-over-year to nearly $12.00 billion, exceeding consensus estimates.

In a move reflecting growing confidence in the healthcare sector's growth trajectory, Thermo Fisher Scientific has raised its full-year financial outlook following a robust second-quarter performance. According to reports, the upward revision is driven by improved customer activity and strategic contributions from recent acquisitions, alongside adjusted earnings per share of $6.03 which beat the $5.71 consensus. Furthermore, the company's adjusted operating margin expanded to 22.8%, underscoring strong operational efficiency and cost management.

Following the guidance hike, RBC Capital raised its price target for TMO to $580 from $490, joining Jefferies which recently set a target of $630. Per market data, the company's Laboratory Products and Biopharma Services segment grew 11.6% to $6.70 billion, while Life Sciences Solutions contributed $2.80 billion in sales. These figures highlight Thermo Fisher's ability to drive organic growth and integrate acquisitions effectively despite broader macroeconomic shifts.

TMO stock stood at $526.46 at close on July 22, 2026, with investors eyeing the recent day high of $528.81 as a key technical level. Market participants are now focusing on upcoming catalysts, including the Michigan Consumer Sentiment index and US inflation expectations. These indicators will be vital in determining if the positive momentum from the raised guidance and margin expansion can be sustained in the coming weeks.